Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.46 |
| ▸ | ATP4A | P20648 | 2/20 | 0.43 |
| ▸ | ATP4B | P51164 | 2/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875666 | 1.00 | ALDH1A1 (0.51) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL7464979 | 0.84 | ALDH1A1 (0.49) | ALDH1A1ALOX5RAB9AKDM4EAR | |
| SCHEMBL3615585 | 0.83 | ALDH1A1 (0.58) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL28822927 | 0.81 | ALDH1A1 (0.67) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL3612022 | 0.79 | ALDH1A1 (0.49) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL3612019 | 0.79 | ALDH1A1 (0.49) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL3650974 | 0.78 | RAB9A (0.51) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL3650972 | 0.78 | RAB9A (0.51) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL3872177 | 0.77 | ALDH1A1 (0.50) | ALDH1A1ALOX5RAB9AKDM4EHPGD | |
| SCHEMBL3875590 | 0.77 | ALDH1A1 (0.50) | ALDH1A1ALOX5RAB9AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642620-B2 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| CN-101213184-B | Heteroaryl-substituted amides comprising an unsaturated or cyclic linking group and their use as medicaments | SANOFI AVENTIS | 2011-05-25 | — | — | CN | disclosed |
| EP-1904476-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| CN-101213184-A | Heteroaryl-substituted amides comprising an unsaturated or cyclic linking group and their use as medicaments | SANOFI AVENTIS (FR) | 2008-07-02 | — | — | CN | disclosed |
| EP-1904476-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| EP-1741708-A1 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000248-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | ALDH1A1 3143/4885ALOX5 13/4885RAB9A 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.